Delving into the Latest Updates on Tisotumab Vedotin-tftv with Synapse

TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them from growing. The purpose of this study is to learn about possible side effects of TIVDAK, specially to any side effect that is related to the eye. A side effect is anything a medicine does to your body that is not part of how the medicine treats disease.
* This study is seeking for participants who: Are willing to take all the required eye tests
* Have not received TIVDAK before
* Do not have any active eye issues.
Participants will receive TIVDAK once every 3 weeks as an infusion that will be injected into the vein. Participants will visit an eye care provider at 3 stages:
* before starting the treatment,
* before each of the first 9 infusions
* then monthly for 3 months after they stop taking TIVDAK. Treatment with TIVDAK will continue until it is not working anymore against the participant's cancer.

Start Date07 May 2025

Sponsor / Collaborator

Pfizer Inc.

[+1]

NCT05866354

/ CompletedPhase 1

An Open-Label, Phase 1 Trial to Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies

The goal of this clinical trial is to test in Chinese Subjects with Metastatic or Recurrent Solid Malignancies. The main questions it aims to answer are:
* How is the PK of tisotumab vedotin?
* How is the immunogenicity of tisotumab vedotin?
* How is the safety and tolerability of tisotumab vedotin?
* How is the clinical efficacy of tisotumab vedotin? Participants will receive 2.0 mg/kg tisotumab vedotin (up to a maximum of 200 mg in subjects ≥ 100 kg) as a 30-minute IV infusion 1Q3W with the aim to characterize the PK profiles and to evaluate immunogenicity, safety, and tolerability of tisotumab vedotin in the Chinese population.
Subjects will receive study treatment until disease progression or any other discontinuation criteria are met, whichever occurs first. Subjects will undergo an end of treatment (EOT) visit 30 days (± 5 days) after the last dose of study treatment or within 7 days after treatment discontinuation has been decided, whichever occurs later.

Start Date16 Jun 2023

Sponsor / Collaborator

Zai Lab (Shanghai) Co., Ltd.

NCT04697628

/ CompletedPhase 3

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer

This trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cervical cancer that has spread to other parts of the body (metastatic) or has come back after being treated (recurrent).
Participants in this trial will be randomly assigned to one of two groups. One group will be treated with tisotumab vedotin. Participants in the other group will get one of five different chemotherapy drugs (topotecan, vinorelbine, gemcitabine, pemetrexed, or irinotecan). Participants and their doctors will know which group they are in. Participants in the chemotherapy group will decide with their study doctor which drug they will take.

Start Date22 Feb 2021

Sponsor / Collaborator

Seagen, Inc.

[+1]

100 Clinical Results associated with Tisotumab Vedotin-tftv

Login to view more data

100 Translational Medicine associated with Tisotumab Vedotin-tftv

Login to view more data

100 Patents (Medical) associated with Tisotumab Vedotin-tftv

Login to view more data

632

Literatures (Medical) associated with Tisotumab Vedotin-tftv

07 Feb 2026·Expert Review of Pharmacoeconomics & Outcomes Research

Cost-effectiveness of second- or third-line treatment with tisotumab vedotin for metastatic or recurrent cervical cancer

Article

Author: Sánchez Vegas, Adrián ; Alegre-Del-Rey, Emilio Jesús ; Briceño-Casado, María del Pilar ; Olry de Labry Lima, Antonio

OBJECTIVE:

To evaluate the cost-effectiveness of tisotumab vedotin (TV) versus single-agent chemotherapy in recurrent or metastatic cervical cancer (r/mCC) after failure of first-line treatment, from the perspective of the Spanish National Health System.

METHODS:

Cost-utility analysis was conducted using a partitioned survival model with three health states, over a 60-month time horizon. Efficacy data ‒overall survival (OS) and progression free survival‒ were derived from innovaTV-301 trial and modeled using parametric survival functions. Costs and utilities were obtained from national databases and literature, with outcomes expressed in quality-adjusted life years (QALYs). Incremental cost-utility ratio (ICUR) was calculated, and sensitivity analyses were performed to explore uncertainty.

RESULTS:

TV provided an additional 0.341 QALYs over chemotherapy (1.229 vs. 0.889) at an incremental cost of €12,138, resulting in an ICUR of €35,600/QALY, assuming a cost equivalent to cemiplimab. Sensitivity analyses showed ICURs ranging from €33,483-€37,564/QALY depending on modeling assumptions. Drug price and OS benefit were the most influential parameters. Using the foreign list price for TV, the ICUR increased to €950,017/QALY.

CONCLUSIONS:

TV offers a modest benefit over chemotherapy in r/mCC and reaches or surpasses the upper bounds of ICER applied in Spain when priced comparably to cemiplimab. The magnitude of clinical benefit remains uncertain.

31 Dec 2025·mAbs

A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity

Article

Author: Gesner, Thomas ; Logel, Claude ; Xie, Kathleen T. ; Cebe, Regis ; Wu, Nila C. ; Li, Xun ; Shi, Xingyi ; Simmons, Quincey ; Velazquez, Roberto ; Tschantz, William R. ; Sagar, Vivek ; Hainzl, Dominik ; Korn, Joshua ; Barzaghi-Rinaudo, Patrizia ; Malamas, Anthony ; Mercan, Samuele ; Green, Andrew ; McLaughlin, Margaret ; Huber, Thomas ; Mueller, Kathrin ; D’Alessio, Joseph A. ; Synan, Alyssa

P-cadherin (pCAD) and LI-cadherin (CDH17) are cell-surface proteins belonging to the cadherin superfamily that are both highly expressed in colorectal cancer. This co-expression profile presents a novel and attractive opportunity for a dual targeting approach using an antibody-drug conjugate (ADC). In this study, we used a unique avidity-driven in vitro screening approach to generate pCAD x CDH17 bispecific antibodies that selectively target cells expressing both antigens over cells expressing only pCAD or only CDH17. Based on in vitro binding and inhibition of cell proliferation results, we selected a lead bispecific antibody to link to the cytotoxic payload monomethyl auristatin E (MMAE) to generate a pCAD x CDH17 bispecific MMAE ADC. In in vivo dual flank mouse models, we demonstrated antitumor activity of the bispecific ADC in tumors expressing both antigens but not in tumors expressing only pCAD or only CDH17. Overall, the preclinical data presented here support the proof-of-concept bispecific antibody discovery approach, demonstrating a rational design for screening antibodies by prioritizing cross-arm avid IgGs to target dual-positive cells.

01 Dec 2025·Gan to kagaku ryoho. Cancer & chemotherapy

[Latest Drug Therapies for Cervical Cancer].

Article

Author: Matsumoto, Koji ; Fujisaki, Motoko

Cervical cancer remains a major global health burden, with limited therapeutic outcomes in advanced and recurrent settings. For locally advanced disease, cisplatin-based chemoradiotherapy(CRT)has long been the standard of care; however, the advent of immune checkpoint inhibitors(ICIs)and antibody-drug conjugates(ADCs)has recently reshaped the treatment landscape. The phase Ⅲ KEYNOTE-826 trial demonstrated that pembrolizumab combined with chemotherapy significantly improved overall survival(OS)in recurrent or metastatic cervical cancer, establishing a new first-line standard. Moreover, the KEYNOTE-A18 trial showed that pembrolizumab in combination with CRT followed by maintenance therapy achieved a 36-month OS rate of 82.6%, marking the first major breakthrough in locally advanced disease in approximately 25 years. In parallel, the ADC tisotumab vedotin significantly prolonged OS to 11.5 months in previously treated recurrent or metastatic cases in the phase Ⅲ innovaTV 301 trial and received approval in Japan in March 2025. Current guidelines, including NCCN v1, 2025 and the ESMO/ESGO/ESTRO joint recommendations, endorse ICI-combined CRT for locally advanced disease, ICI plus chemotherapy as first-line treatment for recurrent/metastatic disease, and ADC therapy as the standard second-line option, reflecting a global reorganization of therapeutic algorithms. Future directions include the establishment of predictive biomarkers, deeper understanding of the tumor microenvironment, and optimization of ICI-ADC combination strategies, aiming to realize a personalized treatment paradigm grounded in immune and molecular targeting.

151

News (Medical) associated with Tisotumab Vedotin-tftv

07 Apr 2026

·www.biospace.com

Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer

FDA feedback enables Corbus to proceed with proposed registrational study design and endpoints to support potential accelerated approval in second-line HNSCC and cervical cancer Updated CRB-701 monotherapy data accepted for presentation at ASCO 2026 Dr. Dominic Smethurst to step down as Corbus' Chief Medical Officer on June 30, 2026 NORWOOD, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced broad alignment with the U.S. Food and Drug Administration (FDA) on the registration path for CRB-701, the Company’s next-generation, highly stable Nectin-4 targeting ADC, in head and neck squamous cell carcinoma (HNSCC) and cervical cancer. Corbus also announced that Dr. Dominic Smethurst, MA, MRCP is stepping down from his role as Chief Medical Officer; his last day with the company will be June 30, 2026. The agreed upon second-line registrational study designs for CRB-701 include: HNSCC: a single, randomized controlled study exploring the efficacy and safety of CRB-701 compared to physicians’ choice chemotherapy with potential accelerated approval using objective response rate (ORR) as the primary endpoint and potential full approval granted on overall survival (OS) benefit. Cervical cancer: a single, randomized controlled study exploring the efficacy and safety of CRB-701 compared to physicians’ choice of chemotherapy or Tivdak® with potential accelerated approval using ORR as the primary endpoint and potential full approval granted on OS benefit. Continued interactions with the FDA planned to finalize the protocols and statistical analysis plans for the registrational studies. Updated clinical data from the Phase 1/2 study of CRB-701 in both HNSCC and cervical cancer will be presented at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 29 – June 2 in Chicago. Data will include clinical response durability as well as HNSCC patient subgroup analysis. Corbus previously presented dose optimization data from the study, including encouraging efficacy and safety findings, at the 2025 European Society for Medical Oncology Congress (ESMO 2025). The company also anticipates reporting data with CRB-701 in combination with Keytruda ® in first-line HNSCC patients in Q4 2026 to support potential further registration-enabling trials. “We’re pleased to share this important regulatory update as we continue to progress CRB-701 as a novel oncology therapeutic to address unmet medical needs for patients. We look forward to sharing updated monotherapy data on CRB-701 at ASCO and expect to initiate a registrational study for CRB-701 in second-line HNSCC in mid-2026,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. Dr. Cohen continued, “This milestone marks an important transition from clinical proof of concept to pending late-stage registrational development and the potential for regulatory submission of CRB-701. This year we will be adding several key new senior leaders to best prepare us for this critical next phase. We are very grateful for Dr. Smethurst’s contributions to advance our pipeline programs through early development, well positioning Corbus for continued success.” About CRB-701 CRB-701 (SYS6002) is a next-generation antibody drug conjugate (ADC) targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer. The FDA has granted two Fast Track designations to CRB-701 in HNSCC and cervical cancer. CRB-701 is licensed from CSPC Megalith Biopharmaceutical Co. Ltd. China. About Corbus Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com . Connect with us on X , LinkedIn and Facebook . Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. INVESTOR CONTACTS: Sean Moran Chief Financial Officer Corbus Pharmaceuticals smoran@corbuspharma.com Dan Ferry Managing Director LifeSci Advisors, LLC daniel@lifesciadvisors.com MEDIA CONTACT: Liz Melone Founder & Principal Melone Communications, LLC liz@melonecomm.com

Fast TrackExecutive Change

07 Apr 2026

·allsci.com

Corbus agrees with FDA on Phase III direction of CSPC-licensed Nectin-4 ADC

Corbus Pharmaceuticals (Nasdaq: CRBP) announced that the FDA has aligned with its proposed registrational study designs for CRB-701, a Nectin-4–targeting antibody-drug conjugate (ADC), in second-line head and neck squamous cell carcinoma and cervical cancer, clearing the path toward randomized trials with objective response rate as the primary endpoint for potential accelerated approval. The ongoing Phase I/II study (NCT06265727) is a recruiting, open-label trial enrolling patients with Nectin-4–expressing advanced solid tumors. No patient numbers, dosing, or efficacy data are disclosed in this announcement; updated monotherapy results are scheduled for presentation at the 2026 ASCO Annual Meeting, May 29–June 2 in Chicago. The agreed registrational designs call for two separate randomized controlled studies. In second-line HNSCC, CRB-701 will be compared with physician’s choice chemotherapy, with ORR as the primary endpoint for accelerated approval and overall survival anchoring potential full approval. In cervical cancer, the comparator arm broadens to include physician’s choice chemotherapy or Tivdak (tisotumab vedotin), under the same dual-endpoint framework. Corbus said it expects to initiate the HNSCC registrational study in mid-2026; protocols and statistical analysis plans for both studies remain under finalization with the FDA. No efficacy numbers from the Phase I/II program were released alongside this regulatory update. About CRB-701 CRB-701 is an ADC licensed from China-based CSPC Megalith Biopharmaceutical in 2023 that pairs a Nectin-4–directed antibody with a site-specific, cleavable linker and a homogeneous drug-to-antibody ratio of 2, using monomethyl auristatin E as the cytotoxic payload. The low DAR and site-specific conjugation are designed to reduce free MMAE systemic exposure relative to enfortumab vedotin (Padcev), the approved Nectin-4 ADC whose indication is currently limited to urothelial carcinoma. Whether that structural distinction translates into a differentiated clinical safety profile in HNSCC or cervical cancer remains to be established in the registrational program. The FDA has granted CRB-701 Fast Track designation in both indications. In the second-line HNSCC setting, the approved landscape consists primarily of anti-PD-1 agents — pembrolizumab and nivolumab — along with cetuximab and cytotoxic chemotherapy. With checkpoint inhibitors now embedded in first-line regimens, a growing proportion of patients entering second-line treatment have already progressed on immunotherapy, a population for which no approved targeted option exists. Nectin-4 expression is independent of PD-L1 status, which is the mechanistic basis for CRB-701’s potential activity in this post-IO population, though that hypothesis requires prospective validation. In cervical cancer, tisotumab vedotin received full FDA approval in April 2024 on the strength of overall survival data from the innovaTV 301 Phase III trial, making it the only approved ADC in this setting and the named comparator in Corbus’s registrational design. Tivdak targets tissue factor rather than Nectin-4 and carries a known ocular toxicity burden, including conjunctivitis and keratitis, that has prompted post-marketing monitoring studies. Cross-trial comparisons are limited by differences in patient populations, prior therapy, and trial design, so any inference about how CRB-701’s DAR-2 construct might compare on tolerability remains speculative until head-to-head or at least contemporaneous data are available. The company also disclosed plans to report combination data for CRB-701 plus pembrolizumab (Keytruda) in first-line HNSCC patients in Q4 2026, which could inform whether a broader registration strategy is warranted beyond the second-line setting. Separately, Corbus announced that Chief Medical Officer Dominic Smethurst will step down on June 30, 2026. The company said it plans to add senior leaders in preparation for the registrational phase. Updated CRB-701 monotherapy data, including response durability and HNSCC subgroup analyses, will be presented at ASCO 2026. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Phase 3Drug ApprovalFast TrackImmunotherapyAccelerated Approval

20 Mar 2026

·allsci.com

Pfizer calls halt to Phase I development of Seagen-acquired CD228 ADC

Pfizer has terminated its Phase I PF-08046031 clinical trial in adults with advanced melanoma and other solid tumors, according to an update on ClinicalTrials.gov (NCT06799533). The decision ends clinical development of the company’s sole CD228-directed antibody-drug conjugate, a molecule inherited through its USD 43 billion acquisition of Seagen in 2023. Only 11 participants were enrolled before the study was stopped, and no results have been posted to the registry. The clinicaltrials.gov listing indicates the decision was taken for strategic reasons with no safety or efficacy concerns. PF-08046031, formerly designated SGN-CD228A under Seagen’s pipeline, is a humanized IgG1 monoclonal antibody conjugated to approximately four molecules of monomethyl auristatin E (MMAE) via a cleavable vedotin-type linker. The ADC was designed to bind CD228 — also known as melanotransferrin — on the surface of tumor cells, internalize, and release its cytotoxic payload within the lysosome, disrupting microtubule polymerization and triggering G2/M cell cycle arrest. CD228 is expressed at elevated levels in melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and esophageal cancer, with limited expression in normal tissues. The study was an open-label, single-arm, sequential assignment trial designed to assess dosing levels in patients with metastatic or unresectable cutaneous melanoma previously treated with an anti-PD-1/PD-L1 regimen. The trial included dose-escalation and dose-optimization cohorts in melanoma, with a planned expansion to also include patients with non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal cancer. Context from Pfizer’s broader pipeline activity offers one plausible frame. Following the Seagen acquisition, Pfizer undertook a series of portfolio rationalization exercises, discontinuing 11 programs in late 2024, with additional cuts following shortly after. A separate earlier-stage trial of SGN-CD228A (NCT04042480) was also terminated, leaving no active clinical studies for this molecule. According to public data, Pfizer retains an interest in CD228 in the form of PF-08046049 (SGN-BB228), a CD228 x 4-1BB bispecific currently under Phase I study (NCT05571839), also being targeted towards melanoma. For Pfizer’s broader oncology portfolio, the loss is one of several Seagen-inherited assets shed as the company narrows its ADC strategy. Pfizer retains other ADC programs built on the vedotin/MMAE platform, including the marketed products brentuximab vedotin (Adcetris) and enfortumab vedotin (Padcev), as well as tisotumab vedotin (Tivdak). Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Phase 1AcquisitionADC

100 Deals associated with Tisotumab Vedotin-tftv

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Tisotumab Vedotin-tftv	-	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Advanced Cervical Carcinoma	Japan	Genmab, Inc.	27 Mar 2025
Metastatic Cervical Carcinoma	Macao	Zai Lab Ltd.	06 Aug 2024
Recurrent Cervical Cancer	Macao	Zai Lab Ltd.	06 Aug 2024
Uterine Cervical Cancer	United States	Seagen, Inc.	20 Sep 2021

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic Carcinoma to the Uterine Cervix	Phase 3	United States	Seagen, Inc.	22 Feb 2021
Metastatic Carcinoma to the Uterine Cervix	Phase 3	United States	Genmab A/S	22 Feb 2021
Metastatic Carcinoma to the Uterine Cervix	Phase 3	China	Seagen, Inc.	22 Feb 2021
Metastatic Carcinoma to the Uterine Cervix	Phase 3	China	Genmab A/S	22 Feb 2021
Metastatic Carcinoma to the Uterine Cervix	Phase 3	Japan	Genmab A/S	22 Feb 2021
Metastatic Carcinoma to the Uterine Cervix	Phase 3	Japan	Seagen, Inc.	22 Feb 2021
Metastatic Carcinoma to the Uterine Cervix	Phase 3	Argentina	Seagen, Inc.	22 Feb 2021
Metastatic Carcinoma to the Uterine Cervix	Phase 3	Argentina	Genmab A/S	22 Feb 2021
Metastatic Carcinoma to the Uterine Cervix	Phase 3	Austria	Seagen, Inc.	22 Feb 2021
Metastatic Carcinoma to the Uterine Cervix	Phase 3	Austria	Genmab A/S	22 Feb 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04697628 (innovaTV 301, ESMO_ASIA2025)	Phase 3	Metastatic Carcinoma to the Uterine Cervix Second line \| Third line	74	Tisotumab vedotin	nobpzikmlz(mpjiwfgzus) = jhdsthonkq nvtlzqtovf (olwjgkceuh, 4.8 - 30.3) View more	Positive	07 Dec 2025
				Investigator’s choice of chemotherapy	nobpzikmlz(mpjiwfgzus) = scvgpmmuag nvtlzqtovf (olwjgkceuh, 0.6 - 17.3) View more
NCT03786081 (innovaTV 205, ESMO2025)	Phase 2	Metastatic Carcinoma to the Uterine Cervix First line \| Second line \| Third line	101	Tisotumab vedotin plus carboplatin	yoqaexoyby(vywbqkmklt) = kzzwchehbq gmrvzencfd (knjvygakah ) View more	Positive	17 Oct 2025
				Tisotumab vedotin plus pembrolizumab	yoqaexoyby(vywbqkmklt) = snnybqldfx gmrvzencfd (knjvygakah ) View more
NCT04697628 (innovaTV 301, Company_Website) Manual	Phase 3	Uterine Cervical Cancer	-	TIVDAK	xipzlxchfg(nhrxgalckr) = filsercuyc gnjojwxlpt (bbqzjouwjk )	Positive	15 Jan 2025
				Chemotherapy	xipzlxchfg(nhrxgalckr) = bfgqtnnkde gnjojwxlpt (bbqzjouwjk, 6.0 - NR)
NCT04697628 (innovaTV 301/ENGOT-cx12/GOG 3057 \| SGNTV-003 \| GOG-3057 \| innovaTV 301 \| ENGOT-cx12 \| innovaTV 301/ENGOT-cx12/GOG-3057, CTgov)	Phase 3	Metastatic Carcinoma to the Uterine Cervix	502	tisotumab vedotin (Tisotumab Vedotin)	qpvtwreblf(nlyjubhuwp) = zofwpwvego wcorkutfpu (luqyjieenh, xfdxigtawo - hhmxchxbbh) View more	-	09 Aug 2024
				pemetrexed+gemcitabine+Vinorelbine+irinotecan+Topotecan (Chemotherapy)	qpvtwreblf(nlyjubhuwp) = nydgxzfhgp wcorkutfpu (luqyjieenh, rcdeawgmhw - qwvgasrwaw) View more
NCT04697628 (innovaTV 301, Pubmed \| N Engl J Med) Manual	Phase 3	Recurrent Cervical Cancer Second line \| Third line	502	Tisotumab vedotin	ktbqglexhk(hmlbixwvnz) = ahbgcgciga nbhxxbyadr (otblhpgqqo, 9.8 - 14.9) View more	Positive	04 Jul 2024
				Chemotherapy (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed)	ktbqglexhk(hmlbixwvnz) = izidzbmeqf nbhxxbyadr (otblhpgqqo, 7.9 - 10.7) View more
NCT03485209 (innovaTV 207, ASCO2024) Manual	Phase 2	Squamous Cell Carcinoma of Head and Neck	40	Tisotumab vedotin	xvzbfpyhre(jnoptobltf) = eeqsjoxbir xodhnfwfmc (ockftojrug, 18.6 - 49.1) View more	Positive	24 May 2024
				Tisotumab vedotin (≤2 prior lines)	xvzbfpyhre(jnoptobltf) = woqxiitsjm xodhnfwfmc (ockftojrug, 21.1 - 61.3) View more
NCT04697628 (ENGOT-cx12 \| GOG-3057 \| innovaTV 301, ASCO2024) Manual	Phase 3	Uterine Cervical Cancer Second line \| Third line	502	Tisotumab vedotin (TV)	gqevrnpltt(lnpmdjbutl) = pqzpwdwpmb nksetaqzxl (bksazihjlx, 13.3 - 23.1) View more	Positive	24 May 2024
				Chemotherapy	gqevrnpltt(lnpmdjbutl) = vyzydcqmzf nksetaqzxl (bksazihjlx, 2.8 - 8.8) View more
NCT04697628 (innovaTV 301 \| ENGOT-Cx12 \| GOG-3057, ESGO2024) Manual	Phase 3	Uterine Cervical Cancer Second line tissue factor	502	Tisotumab vedotin	sfkusuxwqi(eadzykrrkc) = ouqdazrupl qnylswippo (mzotmmdiee, 9.8 - 14.9) View more	Positive	10 Mar 2024
				investigator’s choice of chemotherapy	sfkusuxwqi(eadzykrrkc) = gjqraibjxs qnylswippo (mzotmmdiee, 7.9 - 10.7) View more
NCT03786081 (innovaTV 205/GOG-3024/ENGOT-cx8, Pubmed \| J Clin Oncol)	Phase 1/2	Metastatic Carcinoma to the Uterine Cervix First line \| Third line tissue factor	142	Tisotumab vedotin + Pembrolizumab	kvvcjxrxuo(trvjsthvtx) = bsdhgyetdn pfuyghzaut (jejffinezh, 23.7 - 59.4) View more	Positive	20 Dec 2023
				Tisotumab vedotin + Carboplatin	kvvcjxrxuo(trvjsthvtx) = hziwpehydh pfuyghzaut (jejffinezh, 36.4 - 71.9) View more
NCT04697628 (innovaTV 301 \| SGNTV-003 \| GOG-3057 \| ENGOT-cx12, ESMO 12023 \| ESMO 22023) Manual	Phase 3	Uterine Cervical Cancer Third line \| Second line	502	Tisotumab vedotin	bntrfizxnc(jiasbilijj) = bzyectfzib afzxbweqcq (ccjstiwqra, 9.8 - 14.9) View more	Positive	22 Oct 2023
				Investigator's choice of chemotherapy	bntrfizxnc(jiasbilijj) = gjivohpesm afzxbweqcq (ccjstiwqra, 7.9 - 10.7) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Tisotumab Vedotin-tftv

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation